52 related articles for article (PubMed ID: 22845710)
1. Minimal clinically important difference in Parkinson's disease as assessed in pivotal trials of pramipexole extended release.
Hauser RA; Gordon MF; Mizuno Y; Poewe W; Barone P; Schapira AH; Rascol O; Debieuvre C; Fräßdorf M
Parkinsons Dis; 2014; 2014():467131. PubMed ID: 24800101
[TBL] [Abstract][Full Text] [Related]
2. Effects of supplementary Da Dingfeng Zhu therapy on patients with Parkinson's disease of liver-kidney yin deficiency pattern.
Liu M; Jia Z; Yao T; Zhang G; Wang X
Parkinsonism Relat Disord; 2024 Jun; 123():106560. PubMed ID: 38518544
[TBL] [Abstract][Full Text] [Related]
3. Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open-label ADS-5102.
Isaacson SH; Fahn S; Pahwa R; Tanner CM; Espay AJ; Trenkwalder C; Adler CH; Patni R; Johnson R
Mov Disord Clin Pract; 2018; 5(2):183-190. PubMed ID: 29780852
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of a once-daily extended-release formulation of pramipexole switched from an immediate-release formulation in patients with advanced Parkinson's disease: results from an open-label study.
Takanashi M; Shimo Y; Hatano T; Oyama G; Hattori N
Drug Res (Stuttg); 2013 Dec; 63(12):639-43. PubMed ID: 23884661
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of pramipexole ER versus IR in Chinese patients with Parkinson's disease: a randomized, double-blind, double-dummy, parallel-group study.
Wang Y; Sun S; Zhu S; Liu C; Liu Y; Di Q; Shang H; Ren Y; Lu C; Gordon MF; Juhel N; Chen S
Transl Neurodegener; 2014; 3():11. PubMed ID: 25114789
[TBL] [Abstract][Full Text] [Related]
6. Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial.
Schapira AH; McDermott MP; Barone P; Comella CL; Albrecht S; Hsu HH; Massey DH; Mizuno Y; Poewe W; Rascol O; Marek K
Lancet Neurol; 2013 Aug; 12(8):747-55. PubMed ID: 23726851
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.
Utsumi H; Okuma Y; Kano O; Suzuki Y; Iijima M; Tomimitsu H; Hashida H; Kubo S; Suzuki M; Nanri K; Matsumura M; Murakami H; Hattori N;
Intern Med; 2013; 52(3):325-32. PubMed ID: 23370739
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group.
JAMA; 1997 Jul; 278(2):125-30. PubMed ID: 9214527
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson's disease.
Hauser RA; Schapira AH; Barone P; Mizuno Y; Rascol O; Busse M; Debieuvre C; Fraessdorf M; Poewe W;
Eur J Neurol; 2014 May; 21(5):736-43. PubMed ID: 24834511
[TBL] [Abstract][Full Text] [Related]
10. Comparison of nocturnal symptoms in advanced Parkinson's disease patients with sleep disturbances: pramipexole sustained release versus immediate release formulations.
Xiang W; Sun YQ; Teoh HC
Drug Des Devel Ther; 2018; 12():2017-2024. PubMed ID: 30013321
[TBL] [Abstract][Full Text] [Related]
11. Analysis of pramipexole dose-response relationships in Parkinson's disease.
Wang Y; Sun SG; Zhu SQ; Liu CF; Liu YM; Di Q; Shang HF; Ren Y; Xiang W; Chen SD
Drug Des Devel Ther; 2017; 11():83-89. PubMed ID: 28096656
[TBL] [Abstract][Full Text] [Related]
12. Auditory musical hallucinations associated with extended-release pramipexole in an elderly patient with Parkinson's disease.
Kataoka H; Ueno S
Medicine (Baltimore); 2014 Dec; 93(27):e251. PubMed ID: 25501095
[TBL] [Abstract][Full Text] [Related]
13. Pramipexole extended-release: a review of its use in patients with Parkinson's disease.
Frampton JE
Drugs; 2014 Dec; 74(18):2175-90. PubMed ID: 25385556
[TBL] [Abstract][Full Text] [Related]
14. Early versus delayed initiation of pharmacotherapy in Parkinson's disease.
Löhle M; Ramberg CJ; Reichmann H; Schapira AH
Drugs; 2014 Apr; 74(6):645-57. PubMed ID: 24756431
[TBL] [Abstract][Full Text] [Related]
15. Initial treatment of Parkinson's disease: an update.
Kaplan S; Tarsy D
Curr Treat Options Neurol; 2013 Aug; 15(4):377-84. PubMed ID: 23645294
[TBL] [Abstract][Full Text] [Related]
16. Pramipexole extended release: a novel treatment option in Parkinson's disease.
Eisenreich W; Sommer B; Hartter S; Jost WH
Parkinsons Dis; 2010 Dec; 2010():612619. PubMed ID: 21209705
[TBL] [Abstract][Full Text] [Related]
17. Success rate, efficacy, and safety/tolerability of overnight switching from immediate- to extended-release pramipexole in advanced Parkinson's disease.
Schapira AH; Barone P; Hauser RA; Mizuno Y; Rascol O; Busse M; Debieuvre C; Fraessdorf M; Poewe W
Eur J Neurol; 2013 Jan; 20(1):180-7. PubMed ID: 22845710
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
